Marcia Wang

Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.

M. Kozal, P. Cahn, J. Aberg, 2020, The lancet. HIV.

Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals

D. Cella, M. Murray, S. Anderson, 2021, The Patient - Patient-Centered Outcomes Research.

Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1

M. Kozal, P. Cahn, M. Krystal, 2022, Antimicrobial agents and chemotherapy.

Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1

M. Kozal, J. Aberg, A. Streinu-Cercel, 2021, AIDS.